The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog

Journal of Veterinary Pharmacology and Therapeutics

Volumn 37, Issue 3, 2014, Pages 279-285

  Collard, W T ^a   Hummel, B D ^a   Fielder, A F ^a   King, V L ^a   Boucher, J F ^a   Mullins, M A ^a   Malpas, P B ^a   Stegemann, M R ^b  

^a ZOETIS   (United States)

^b Zoetis Veterinary Medicine Research and Development   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

OCLACITINIB; DERMATOLOGICAL AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MONGREL DOG; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT; ANIMAL; BIOAVAILABILITY; BLOOD; CROSSOVER PROCEDURE; DOG; HALF LIFE TIME; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

CANIS FAMILIARIS;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DOGS; FEMALE; HALF-LIFE; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 84899932531     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12087     Document Type: Article

References (19)

1. Carmi-Levy, I., Homey, B., & Soumelis, V. (2011) A modular view of cytokine networks in atopic dermatitis. Clinical Reviews in Allergy and Immunology, 41, 245-253.
2. Cosgrove, S.B., Wren, J.A., Cleaver, D.M., Martin, D.D., Walsh, K.F., Harfst, J. A., Follis, S.L., King, V.L., Boucher, J.F. & Stegemann, M.R. (2013) Efficacy and safety of oclacitinib in the treatment of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 24, 479-e114.
3. ®;) in client-owned dogs with atopic dermatitis. Veterinary Dermatology, 24, 587-e142.
4. Fleck, T., Humphrey, W., Coscarelli, E., Galvan, B., Aleo, M., Gonzales, A., Shelly, J., Mahabir, S. & McCall, R. (2012) Comparison of the janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Veterinary Dermatology, 23(Suppl 1), 38.
5. Ghoreschi, K., Laurence, A. & O'Shea, J.J. (2009) Janus kinases in immune cell signaling. Immunological Reviews, 228, 273-287.
6. Gonzales, A.J., Humphrey, W., Messamore, J.E., Fleck, T.J., Fici, G.J., Shelly, J.A., Teel, J.F., Bammert, G.F., Dunham, S.A., Fuller, T.E. & McCall, R.B. (2012) IL-31: its role in canine pruritus and prevalence in naturally occurring canine atopic dermatitis. Veterinary Dermatology, 23(Suppl. 1), 6.
7. Gonzales, A.J., Bowman, J., Fici, G., Zhang, M. & Mann, D.M. (2013) Oclacitinib (Apoquel, Zoetis) is a novel Janus kinase inhibitor that has activity against canine pro-allergic and pro-inflammatory cytokines A. J. Gonzales, ESVD Abstract # 40 Valencia Spain September 2013. Veterinary Dermatology 24, 384.
8. Gough, K., Hutchison, M., Keene, O., Byrom, B., Ellis, S., Lacey, L. & McKellar, J. (1995) Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Information Journal, 29, 1039-1048.
9. Guidance for industry 145: Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), May 2001
10. Hummel, J., McKendrick, S., Brindley, C. & French, R. (2009) Exploratory assessment of dose proportionality: Review of current approaches and proposal for a practical criterion. Pharmaceutical Statistics, 8, 38-49.
11. Klamerus, K.J., Maloney, K., Rudolph, R.L., Sisenwine, S.F., Jusko, W.J. & Chiang, S.T. (1992) Introduction of a composite parameter to the pharmacokinetics of Venalfaxine and its active O-desmethyl metabolite. Journal of Clinical Pharmacology, 32, 716-724.
12. Mahar, K.M., Portelli, S., Coatney, R. & Chen, E.P. (2012) Gastric pH and gastric residence time in fasted and fed conscious beagle dogs using the Bravo pH system. Journal of Pharmaceutical Sciences, 101, 2439-2448.
13. Marsella, R., Sousa, C.A., Gonzales, A.J. & Fadok, V.A. (2012) Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. Journal of the American Veterinary Medical Association, 241, 194-207.
14. Martinez, M.N. & Papich, M.G. (2012) Drug solubility classification in the dog. Journal of Veterinary Pharmacology and Therapeutics, 35(Suppl 1), 87-91.
15. Ong, P.Y. & Leung, D.Y. (2006) Immune dysregulation in atopic dermatitis. Current Allergy and Asthma Reports, 6, 384-389.
16. Quintás-Cardama, A., Kantarjian, H., Cortes, J. & Verstovsek, S. (2011) Janus kinas inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews Drug Discovery, 10, 127-140.
17. Sagawa, K., Li, F., Liese, R. & Sutton, S.C. (2009) Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. Journal of Pharmaceutical Sciences, 98, 2494-2500.
18. Smith, B.P., Vandenhende, F.R., DeSante, K.A., Farid, N.A., Welch, P.A., Callaghan, J.T. & Forgue, S.T. (2000) Confidence Interval Criteria for Assessment of Dose Proportionality. Pharmaceutical Research, 17, 1278-1283.
19. Toutain, P.L. & Bousquet-Melou, A. (2004) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415-425.